ZA201003908B - Kappa selective opioid receptor antagonist - Google Patents
Kappa selective opioid receptor antagonistInfo
- Publication number
- ZA201003908B ZA201003908B ZA2010/03908A ZA201003908A ZA201003908B ZA 201003908 B ZA201003908 B ZA 201003908B ZA 2010/03908 A ZA2010/03908 A ZA 2010/03908A ZA 201003908 A ZA201003908 A ZA 201003908A ZA 201003908 B ZA201003908 B ZA 201003908B
- Authority
- ZA
- South Africa
- Prior art keywords
- receptor antagonist
- opioid receptor
- selective opioid
- kappa selective
- kappa
- Prior art date
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 title 1
- 239000003401 opiate antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| PCT/US2009/030811 WO2009094260A1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201003908B true ZA201003908B (en) | 2011-11-30 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/03908A ZA201003908B (en) | 2008-01-22 | 2010-06-01 | Kappa selective opioid receptor antagonist |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2712347A1 (en) * | 2008-01-22 | 2009-07-30 | Takeda Pharmaceutical Company Limited | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| EP2252581B1 (en) * | 2008-01-22 | 2012-06-20 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| EP2757881A4 (en) | 2011-09-15 | 2014-11-12 | Univ Kansas | KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF |
| US10813925B2 (en) | 2011-09-19 | 2020-10-27 | Carmel—Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| EP2773352B1 (en) | 2011-12-09 | 2017-06-28 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| HK1215170A1 (zh) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | 治療精神分裂症的方法和組合物 |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| WO2014190270A1 (en) * | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| CN110914262B (zh) | 2017-03-17 | 2024-04-05 | 斯克里普斯研究所 | κ阿片受体拮抗剂以及与其相关的产品和方法 |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| IL308221A (en) | 2021-05-04 | 2024-01-01 | Janssen Pharmaceuticals Inc | Preparations and methods for treating depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| KR20240132501A (ko) * | 2022-01-10 | 2024-09-03 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
| EP4463152A1 (en) * | 2022-01-10 | 2024-11-20 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| KR20240152410A (ko) * | 2022-03-07 | 2024-10-21 | 얀센 파마슈티칼즈, 인코포레이티드 | 아티카프란트를 포함하는 조성물 |
| JP2025508071A (ja) * | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 純粋な形態の結晶質アチカプラント |
| TW202345796A (zh) | 2022-03-07 | 2023-12-01 | 美商健生醫藥公司 | 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| ES2189759T3 (es) * | 1999-05-12 | 2003-07-16 | Hoffmann La Roche | Derivados de imidazoiacepina. |
| CA2425124A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| ATE389640T1 (de) * | 2002-03-28 | 2008-04-15 | Wisys Technology Found Inc | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| MXPA05003093A (es) * | 2002-09-19 | 2005-07-13 | Lilly Co Eli | Diaril eteres como antagonistas de receptor opiode. |
| CN1756746A (zh) | 2003-03-07 | 2006-04-05 | 伊莱利利公司 | 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物 |
| MXPA05009367A (es) | 2003-03-07 | 2005-11-04 | Lilly Co Eli | Antagonistas del receptor opioide. |
| US7196100B2 (en) | 2003-12-12 | 2007-03-27 | Eli Lilly And Company | Opioid receptor antagonists |
| AU2004312312A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
| CA2558652A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| ES2347577T3 (es) | 2004-03-12 | 2010-11-02 | Eli Lilly And Company | Antagonistas de receptores opioides. |
| EP1729759A4 (en) | 2004-03-12 | 2008-04-02 | Mclean Hospital Corp | SALVINORINE DERIVATIVES AND ITS USES |
| JP2007529523A (ja) | 2004-03-15 | 2007-10-25 | イーライ リリー アンド カンパニー | 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物 |
| EP1735268B1 (en) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| US8551986B2 (en) | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| PL2001456T3 (pl) | 2006-04-04 | 2010-05-31 | Emodys Gmbh | Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych |
| US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
| EP2049481A2 (en) | 2006-08-09 | 2009-04-22 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| CA2662766C (en) | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| EP2252581B1 (en) * | 2008-01-22 | 2012-06-20 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
-
2009
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL206038A0 (en) | Kappa selective opioid receptor antagonist | |
| EP2252150A4 (en) | SELECTIVE OPIOID COMPOUNDS | |
| EP2034832A4 (en) | IL-8 RECEPTOR ANTAGONIST | |
| EP2184278A4 (en) | P2X4 RECEIVER ANTAGONIST | |
| EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| ZA201203452B (en) | Cgrp receptor antagonists | |
| IL212551A0 (en) | Cxcr4 receptor compounds | |
| ZA200808358B (en) | IL-8 receptor antagonists | |
| IL213112A0 (en) | Nalmefene hydrochloride dihydrate | |
| IL194700A0 (en) | Il-8 receptor antagonists | |
| EP2099300A4 (en) | IL-8 RECEPTOR ANTAGONISTS | |
| EP2191830A4 (en) | SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST | |
| IL217526A0 (en) | Carbocyclic glyt1 receptor antagonists | |
| ZA201005341B (en) | Methods for inhibiting angiogenesis using egfl8 antagonists | |
| IL207700A0 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists | |
| ZA200903523B (en) | Poly-TLR antagonist | |
| GB0701632D0 (en) | MET receptor antagonists | |
| GB0922455D0 (en) | Ep2 receptor antagonists | |
| GB0900755D0 (en) | Ep4 receptor antagonists | |
| GB0900754D0 (en) | EP4 Receptor antagonists | |
| GB0900756D0 (en) | EP4 Receptor antagonists |